Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

cardiac damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adrenergic Receptor (2) Akt (5) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (10) Autophagy (7) Bacterial (2) Dopamine β-hydroxylase (2) ERK (3) Ferroptosis (1) Fungal (2) GnRH Receptor (1) HIV (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (2) Leukotriene Receptor (8) MEK (3) Mitochondrial Metabolism (4) mTOR (2) Na+/H+ Exchanger (NHE) (1) NF-κB (5) NOD-like Receptor (NLR) (1) Oxidative Phosphorylation (1) PERK (2) PI3K (5) PKC (1) PTEN (3) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Reference Standards (6) SGLT (1) SOD (1) TGF-beta/Smad (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (19) Endocrinology (2) Infection (5) Inflammation/Immunology (17) Metabolic Disease (4) Neurological Disease (6)

By Targets:

Acyltransferase (1)

Adrenergic Receptor (2)

Akt (5)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (10)

Autophagy (7)

Bacterial (2)

Dopamine β-hydroxylase (2)

ERK (3)

Ferroptosis (1)

Fungal (2)

GnRH Receptor (1)

HIV (1)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (2)

Leukotriene Receptor (8)

MEK (3)

Mitochondrial Metabolism (4)

mTOR (2)

Na+/H+ Exchanger (NHE) (1)

NF-κB (5)

NOD-like Receptor (NLR) (1)

Oxidative Phosphorylation (1)

PERK (2)

PI3K (5)

PKC (1)

PTEN (3)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (6)

SGLT (1)

SOD (1)

TGF-beta/Smad (2)

By Research Areas:

Cancer (14)

Cardiovascular Disease (19)

Endocrinology (2)

Infection (5)

Inflammation/Immunology (17)

Metabolic Disease (4)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111475

Mitochondrial fusion promoter M1 2 Publications Verification	Mitochondrial Metabolism	Cardiovascular Disease
Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury .

HY-N3121

Pachypodol	PERK Keap1-Nrf2 Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pachypodol is an orally active methoxyflavonoid compound. Pachypodol activates the ERK-dependent Nrf2 pathway and inhibits Apoptosis. Pachypodol exhibits activities such as antioxidant, cytoprotective, anti-inflammatory effects. Pachypodol improves cognition. Pachypodol exerts protective effects against cardiac and liver damage. Pachypodol has anticancer activity against colon cancer .

HY-111536

Mitochonic acid 5 4 Publications Verification MA-5	Oxidative Phosphorylation Mitochondrial Metabolism	Cardiovascular Disease
Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. Mitochonic acid 5 modulates mitochondrial ATP synthesis.

HY-W018026

Oxfenicine L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842	Acyltransferase Apoptosis	Cardiovascular Disease Metabolic Disease
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .

HY-N6020B

Butin	Others	Cardiovascular Disease Inflammation/Immunology
Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera with oral activity, with strong antioxidant, antiplatelet and anti-inflammatory activities. Butin significantly alleviates myocardial infarction and improves heart function, together with prevents diabetes-induced cardiac oxidative damage in rat .

HY-W021040

Fludioxonil CGA-173506	Fungal Apoptosis	Infection Cancer
Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

HY-130272

Anti-MI/R injury agent 1	Others	Cardiovascular Disease
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .

HY-110075

Dexrazoxane monohydrochloride	Others	Cardiovascular Disease
Dexrazoxane monohydrochloride is the hydrochloride of Dexrazoxane (HY-B0581). Dexrazoxane can prevent or reduce cardiac damage and is an iron chelator and apoptosis inducer. Dexrazoxane has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities and inhibits ferroptosis .

HY-13315S1

Montelukast-d6 sodium MK0476-d₆	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-13315S

Montelukast-d6 MK0476-d₆ free acid	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-B0655

Zofenopril calcium SQ26991	Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS)	Cardiovascular Disease
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A).

HY-P5452

PKCd (8-17)	PKC	Others
PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)

HY-W021040S

Fludioxonil-13C3 CGA-173506-¹³C₃	Isotope-Labeled Compounds Fungal Apoptosis	Infection Cancer
Fludioxonil- ¹³C₃ (CGA-173506- ¹³C₃) is ¹³C labeled Fludioxonil. Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

HY-13315

Montelukast sodium Maximum Cited Publications 11 Publications Verification MK0476	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315A

Montelukast Maximum Cited Publications 11 Publications Verification MK0476 free base	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-N3121R

Pachypodol (Standard)	Reference Standards PERK Keap1-Nrf2 Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pachypodol (Standard) is the analytical standard of Pachypodol (HY-N3121). This product is intended for research and analytical applications. Pachypodol is an orally active methoxyflavonoid compound. Pachypodol activates the ERK-dependent Nrf2 pathway and inhibits Apoptosis. Pachypodol exhibits activities such as antioxidant, cytoprotective, anti-inflammatory effects. Pachypodol improves cognition. Pachypodol exerts protective effects against cardiac and liver damage. Pachypodol has anticancer activity against colon cancer .

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-N13218

Pueraria Extract	Others	Cardiovascular Disease
Pueraria Extract is a kudzu extract, and its components include: Isoflavones. Pueraria Extract (ethanol extract) can significantly improve cardiac damage in rats with acute myocardial infarction. Pueraria Extract improves bile acid levels by increasing the expression of CYP7A1 and restoring the diversity of intestinal microbiota. Pueraria Extract can also inhibit the FXR-FGF15 signaling pathway and increase the expression of OST-α to increase bile acid reabsorption and fecal excretion. .

HY-P5762A

Phoenixin-14 TFA PNX-14 TFA	GnRH Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Phoenixin-14 (PNX-14) TFA, a neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH .

HY-13315R

Montelukast sodium (Standard) MK0476 (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315AR

Montelukast (Standard) MK0476 free base (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-13315BR

Montelukast dicyclohexylamine (Standard) MK0476 dicyclohexylamine (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-155517

INF200	NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology
INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .

HY-N1441

Afzelin 5+ Cited Publications Kaempferol-3-O-rhamnoside	Mitochondrial Metabolism PTEN Autophagy Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .

HY-174400

SGLT2-IN-2	SGLT SOD Na+/H+ Exchanger (NHE) Autophagy	Cardiovascular Disease
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .

HY-N1441R

Afzelin (Standard) Kaempferol-3-O-rhamnoside (Standard)	Mitochondrial Metabolism PTEN Autophagy Bacterial Reference Standards	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
Afzelin (Standard) is the analytical standard of Afzelin. This product is intended for research and analytical applications. Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .

HY-N1487

Oleanonic acid 1 Publications Verification 3-Oxooleanolic acid	HIV Autophagy Ferroptosis Amyloid-β	Infection Neurological Disease Inflammation/Immunology Cancer
Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats .

HY-128483

Fusaric acid	TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β₁/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .

HY-N0103A

Sophocarpine monohydrate 5+ Cited Publications	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK	Cardiovascular Disease Inflammation/Immunology Cancer
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-N0103

Sophocarpine 5+ Cited Publications	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK PTEN	Cardiovascular Disease Inflammation/Immunology Cancer
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-128483R

Fusaric acid (Standard)	TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β₁/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .

HY-N0103R

Sophocarpine (Standard)	Reference Standards Autophagy Apoptosis NF-κB PI3K Akt MEK ERK	Cardiovascular Disease Inflammation/Immunology Cancer
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

Cat. No.	Product Name	Target	Research Area